Conduent (CNDT) Q2 2026 Earnings Call Transcript
Conduent (CNDT) reported Q2 2026 revenue of $531 million, down 11.9%, and adjusted EBITDA of $16 million, down 30.4%, citing contract losses and volume declines. Qualified pipeline was $3 billion, and it guided full-year revenue to $2.15–$2.25 billion and adjusted EBITDA to $140–$170 million. The company expects $234 million from divesting transit and tolling businesses.
How this was made
The 30-second read
Why it matters
The call provides a full set of trader-relevant metrics: revenue and adjusted EBITDA declines, updated full-year guidance, cash flow and leverage framing around divestiture proceeds, and explicit risk commentary about stranded costs and ongoing contract roll-offs.
Market read
This is a guidance-and-profitability reset story: investors get updated 2026 ranges, cash/leverage framing around divestitures, and risk disclosures about stranded costs and contract roll-offs.
What to watch
Stranded costs from the former transportation segment ($4M in 2026, $6M in 2025) and contract roll-offs (including loss of the largest commercial client) could delay margin recovery even if pipeline growth looks healthy.
Background
Conduent held its Q2 2026 earnings call, covering financial performance, portfolio optimization, and progress on operational and AI initiatives.
Ticker impact
Conduent reported Q2 2026 revenue of $531M, cut adjusted EBITDA to $16M, and updated full-year guidance to $2.15B-$2.25B revenue and $140M-$170M adjusted EBITDA.
Bias toward downside or higher volatility until investors see stabilization in contract roll-offs and margin recovery toward the 7% midpoint.
The article discloses multiple decision-relevant datapoints: revenue down 11.9%, adjusted EBITDA down 30.4%, negative adjusted free cash flow, and updated full-year ranges, plus explicit stranded costs and ongoing contract roll-offs.
Market effects
Signals continued pressure in government and commercial services execution, while AI-enabled automation and Medicaid platform modernization are positioned as offsets.
Primarily US public-sector and healthcare administration modernization exposure (Medicaid platforms).
Limited direct global read-through, though management mentions expansion into Canada, Western Europe, and Australia.
Counterpoint
Investors may underweight the near-term EBITDA decline because the company highlights a $3B qualified pipeline, $100M commercial new business ACV, and a $100M cost-savings program on track for most savings in 2026.
Key entities
- companyConduent Incorporated
CNDT, reported Q2 2026 results and updated full-year revenue and adjusted EBITDA guidance alongside divestiture plans.
- executiveHarsha Agadi
CEO, discussed momentum, margin framework, and ongoing contract roll-offs.
- executiveGiles Goodburn
CFO, discussed adjusted EBITDA drivers including stranded costs tied to the former transportation segment.
- counterpartyModaxo
Named as buyer of Conduent’s transit business, with divestiture proceeds expected to contribute to leverage reduction.
- counterpartyQuarterhill
Named as buyer of Conduent’s tolling business, with divestiture proceeds expected to contribute to leverage reduction.
